Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await
The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.
The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.